Loading…
Loading…
SYDNEY, July 23, 2026 (GLOBE NEWSWIRE) -- Brazilian Rare Earths Limited (ASX: BRE / OTCQX: BRELY) ('BRE') is pleased to report progress during the quarter ended 30 June 2026. Highlights during and subsequent to the end of the quarter include: VELHINHAS AIRBORNE GEOPHYSICS AND DRILLING UNLOCKS +9 KM RARE EARTH CORRIDOR IN THE MONTE ALTO DISTRICT New District-Scale Growth Corridor: High-resolution airborne geophysics defined more than 9 km of cumulative exploration corridors across the Velhinhas project, beginning ~5 km south of the ultra-high-grade Monte Alto Deposit and extending rare earth mineralisation to over 8 km south of Monte Alto Multiple Parallel Exploration Trends: The survey confirmed four large-scale north-northeast trending mineralised corridors, converting numerous ultra-high-grade surface results into a district-scale exploration model analogous with the Sulista district opportunity Drilling Results Confirm High-Grade Mineralisation: Reconnaissance diamond drilling returned grades of 19.6% TREO, 33,607 ppm NdPr, 1,463 ppm Dy₂O₃, 248 ppm Tb₄O₇, 7,431 ppm Y₂O₃ and 1,087 ppm U₃O₈ Critical Mineral Grades: High-grade assays are accompanied by NdPr, DyTb, yttrium, niobium, scandium, tantalum and uranium, consistent with BRE's high-value REE-Nb-Sc-Ta-U systems at Monte Alto and Sulista Monte Alto District Growth Accelerates: Velhinhas expands the Monte Alto growth story, highlighting the potential for a district-scale mineral system extending south from the ultra-high-grade Monte Alto Deposit EXCEPTIONAL YTTRIUM-RICH HEAVY RARE EARTH DRILL RESULTS EXPAND THE MONTE ALTO DISTRICT Exceptional heavy rare earth grades: MADD0210 returned 2.5 m at 7.5% TREO from 6.0 m, including 1.3 m at 10.9% TREO from 7.2 m, with 58,249 ppm (5.8%) Y2O3, 4,135 ppm Dy2O3, 488 ppm Tb4O7 and 1,588 ppm U3O8 New high-grade, heavy rare earth target remains open: Auger hole STU2478, located ~200 m southwest of the initial diamond drilling, returned 12 m at 8.7% TREO from 18 m to end of hole, including 1,004 ppm DyTb and 0.44% Y2O3.
Fifth Third Bancorp bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,272 shares of the biopharmaceutical company's stock, valued at approximately $2,310,000. Fifth Third Bancorp owned about 0.11%
LEADING EDGE MATERIALS ADVANCES MIDSTREAM PROCESSING STRATEGY FOR THE NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) against certain of its officers and directors for alleged breaches of fiduciary duty.
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recent Phase 3 failure and Q1 2026 net loss, RARE reaffirmed 2026 revenue guidance of $730–$760 million, supported by a scalable commercial base and cost controls. Key near-term catalysts include FDA reviews for DTX401 and UX111 (PDUFA dates in H2 2026) and pivotal Phase 3 Aspire results for GTX-102 in Angelman syndrome.
NOVATO, Calif. , June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for RARE and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.